Company / Cash & Equivalents
PROKIDNEY CORP. Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$99.1M
FY2024
5-year range
$20.6M / $490.3M
FY2021-FY2024
Trend
+63.4%
vs FY2023
Sector context
#142 of 207
Health Care
What the data says
At $99M, PROKIDNEY CORP.'s cash & equivalents ranks #142 of 207 in the Health Care sector. Declined from $490M to $99M over the past 2 years.
Based on SEC 10-K filings.
$99M in FY2024 with a 3-year CAGR of +68.9%.
Declined from $490M to $99M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +68.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#142 of 207 in Health CareTop 69% of 207This company $99.1M Sector average $669.5M
▼
-85.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +68.9%, indicating consistent growth.
- In FY2024, cash & equivalents increased 63.4% year-over-year.
- Ranks #142 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.00 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $99.1M | +63.4% |
| FY2023 | $60.6M | -87.6% |
| FY2022 | $490.3M | +2284.7% |
| FY2021 | $20.6M | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026